Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.63 |
| ▸ | ABL2 | P42684 | 2/20 | 0.63 |
| ▸ | BRAF | P15056 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 4/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610986 | 0.85 | DDR1 (0.64) | ABL1ABL2KITDDR1 | |
| SCHEMBL13772004 | 0.85 | BRAF (0.64) | ABL1BRAFEGFRRETKIT | |
| SCHEMBL13765913 | 0.84 | ABL1 (0.73) | ABL1ABL2KIT | |
| SCHEMBL9611004 | 0.83 | ABL1 (0.61) | ABL1ABL2KITDDR1 | |
| SCHEMBL15061749 | 0.78 | ABL1 (0.80) | ABL1ABL2BRAFEGFRRET | |
| SCHEMBL19317720 | 0.77 | ABL1 (1.00) | ABL1ABL2KIT | |
| SCHEMBL19317723 | 0.76 | ABL1 (0.81) | ABL1ABL2BRAFEGFRKIT | |
| SCHEMBL15061742 | 0.76 | ABL1 (0.76) | ABL1ABL2BRAFEGFRRET | |
| SCHEMBL10265418 | 0.75 | ABL1 (0.66) | ABL1ABL2BRAFEGFRRET | |
| SCHEMBL9611036 | 0.74 | ABL1 (0.75) | ABL1ABL2BRAFEGFRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | ABL1 1035/4885ABL2 924/4885BRAF 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.